Halozyme Therapeutics
Halozyme's recombinant hyaluronidase (ENHANZE) is what lets antibodies such as rituximab, trastuzumab and daratumumab be given as quick under-the-skin injections instead of long infusions; its own tumour-targeting version failed in pancreatic cancer.
Overview
Halozyme Therapeutics, founded in 1998 in San Diego, licenses its ENHANZE drug-delivery technology, a recombinant human hyaluronidase that breaks down hyaluronan under the skin so large volumes of antibody can be injected subcutaneously; the subcutaneous forms of rituximab, trastuzumab, daratumumab, pertuzumab and atezolizumab rely on it. Its own PEGylated hyaluronidase PEGPH20, aimed at hyaluronan-rich pancreatic tumours, failed the phase 3 HALO-301 trial in 2019. ClinicalTrials.gov lists Halozyme as lead sponsor of that and other phase 3 trials.
Scorecard
All companies- approved products +18
- targets +6
- modalities +2
- regions +7
- 24-month regulatory events +2
- registry trials +30
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
Similar pages
not linked directly; found by shared links- CompanyNippon Kayaku
Shares Trastuzumab, Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyCEBIOTEX
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.